Our CTO Do Won Hwang and CSO Shin-Il Kim, along with CSO Nick Boyd-Gibbins at Therabest Japan, published an article "iPSCs in NK Cell Manufacturing and NKEV Development" in Frontiers in Immunology (IF: 8.786).

This review explores the advantages of using iPSCs (induced Pluripotent Stem Cells) for NK cell manufacturing and translation, and how these trends can extend into the next generation of enhanced NK cell therapies and the emerging field of NK cell-derived extracellular vesicles / exosomes (NKEVs).

Please refer to the following link.

https://www.frontiersin.org/articles/10.3389/fimmu.2022.890894/full